who receive COVID vaccines: A recent study from Yale University in the United States asserts that some people are experiencing “post-vaccination syndrome” (PVS) as a result of the Covid-19 vaccine.
who receive COVID vaccines, The biological causes of this syndrome are not well understood, but the study reports that symptoms like exercise intolerance, extreme fatigue, feeling exhausted, mental fog, insomnia, irregular heartbeat, ringing in the ears, dizziness, muscle pain, and immune system changes have been noted in those who are afflicted. These symptoms start to show up a day or two after receiving the vaccine, and they may get worse over time and last for a long period.
While the Covid vaccination has saved millions of lives during the global epidemic, thousands of people worldwide have reported that it has negatively impacted their health for years. But there hasn’t been much research on PVS particularly, which Dr. Akiko Iwasaki, an immunologist at Yale University, hopes to address with additional studies.
Because PVS is not a recognized medical illness, those with it have been ignored, according to Dr. Iwasaki.
“I think scientific research will help us better diagnose, treat, and prevent PVS. It will also help us understand the safety aspects of vaccines,” he continues.
The study was based on the “Listen to Immune, Symptom, and Treatment Experience Now” (LISTEN) study conducted at Yale University, which had 42 patients with and 22 without PVS symptoms.
The levels of specific immune cells in individuals with PVS differed from those in the control group, according to scientists who examined various immune system components. The study also discovered that the Epstein-Barr virus, which is generally dormant in the body but is connected to multiple sclerosis, mononucleosis, and other illnesses, was reactivated in patients with PVS.
According to experts, this study may provide a significant first step toward understanding the scope of PVS, even though additional research is required.
“This research is still in its early stages, and we need to further confirm these findings,” the research team stated. However, there is some hope that we may eventually find a solution for the diagnosis and management of PVS.
According to experts, a thorough understanding of PVS and its contributing variables will help design vaccinations with fewer adverse effects, improve diagnosis, and identify efficient treatment options.